Preclinical Mammalian Safety Studies of EPHARNA (DOPC Nanoliposomal EphA2-Targeted siRNA)

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-16-0541
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Immunocompetent Mouse Model of Breast Cancer for Preclinical Testing of EphA2-targeted Therapy

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2004English

Codelivery of Doxorubicin and JIP1 siRNA With Novel EphA2-targeted PEGylated Cationic Nanoliposomes to Overcome Osteosarcoma Multidrug Resistance

International Journal of Nanomedicine
Organic ChemistryBiophysicsBiomaterialsPharmaceutical ScienceMedicineBioengineeringDrug DiscoveryNanoscienceNanotechnology
2018English

Peptide-Functionalized Nanogels for Targeted siRNA Delivery

Bioconjugate Chemistry
Organic ChemistryBiotechnologyPharmacologyPharmaceutical ScienceBioengineeringBiomedical Engineering
2009English

Progress in Targeted Delivery of siRNA to Combat Coxsackievirus

Protein & Cell
BiochemistryBiotechnologyDrug DiscoveryCell BiologyMedicine
2011English

Development of Regional Chemotherapies: Feasibility, Safety and Efficacy in Clinical Use and Preclinical Studies

Therapeutic Delivery
Pharmaceutical Science
2011English

Chemosensitization of Cancer Cells by siRNA Using Targeted Nanogel Delivery

BMC Cancer
Cancer ResearchOncologyGenetics
2010English

Clinical Chemistry in Preclinical Safety Assessment

Toxicologic Pathology
Forensic MedicineToxicologyPathologyCell BiologyMolecular Biology
1992English

TARGETED DELIVERY OF siRNA TO CELL DEATH PROTEINS IN SEPSIS

Shock
Critical CareEmergency MedicineIntensive Care Medicine
2009English

Selection of Highly Efficient Small Interference RNA (SiRNA) Targeting Mammalian Genes

Journal of Biophysical Chemistry
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy